Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

• Published in: British journal of cancer 2024-01, Vol.130 (1), p.43-52
• Main Authors: Jo, Jung Hyun, Kim, Yong-Tae, Choi, Ho Soon, Kim, Ho Gak, Lee, Hong Sik, Choi, Young Woo, Kim, Dong Uk, Lee, Kwang Hyuck, Kim, Eui Joo, Han, Joung-Ho, Lee, Seung Ok, Park, Chang-Hwan, Choi, Eun Kwang, Kim, Jae Woo, Cho, Jae Yong, Lee, Woo Jin, Moon, Hyungsik Roger, Park, Mi-Suk, Kim, Sangjae, Song, Si Young
• Format: Article
• Language: English
• Subjects: 692/308/2779/777; 692/4028/67/1504/1713; Adenocarcinoma; Adenocarcinoma - chemically induced; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biomedical and Life Sciences; Biomedicine; Cancer Research; Capecitabine - adverse effects; Deoxycytidine - adverse effects; Drug Resistance; Eotaxin; Epidemiology; Gemcitabine; Humans; Molecular Medicine; Oncology; Pancreas; Pancreatic cancer; Pancreatic Neoplasms - pathology; Patients; Survival
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/s41416-023-02474-w

Background The TeloVac study indicated GV1001 did not improve the survival of advanced pancreatic ductal adenocarcinoma (PDAC). However, the cytokine examinations suggested that high serum eotaxin levels may predict responses to GV1001. This Phase III trial assessed the efficacy of GV1001 with gemcitabine/capecitabine for eotaxin-high patients with untreated advanced PDAC. Methods Patients recruited from 16 hospitals received gemcitabine (1000 mg/m 2 , D 1, 8, and 15)/capecitabine (830 mg/m 2 BID for 21 days) per month either with (GV1001 group) or without (control group) GV1001 (0.56 mg; D 1, 3, and 5, once on week 2–4, 6, then monthly thereafter) at random in a 1:1 ratio. The primary endpoint was overall survival (OS) and secondary end points included time to progression (TTP), objective response rate, and safety. Results Total 148 patients were randomly assigned to the GV1001 ( n  = 75) and control groups ( n  = 73). The GV1001 group showed improved median OS (11.3 vs. 7.5 months, P  = 0.021) and TTP (7.3 vs. 4.5 months, P  = 0.021) compared to the control group. Grade >3 adverse events were reported in 77.3% and 73.1% in the GV1001 and control groups ( P  = 0.562), respectively. Conclusions GV1001 plus gemcitabine/capecitabine improved OS and TTP compared to gemcitabine/capecitabine alone in eotaxin-high patients with advanced PDAC. Clinical trial registration NCT02854072.